Aptevo Therapeutics remains a clinical-stage biotech without revenue from approved products, facing substantial operating losses and ongoing capital needs that raise going concern issues. The company’s development efforts center on immunotherapy candidates mipletamig and ALG.APV-527, leveraging its proprietary ADAPTIR platform amid significant regulatory and clinical execution risks. Expanding operating deficits and negative cash flows underscore reliance on equity purchase agreements to sustain R&D activities. Future progress hinges on successful trial milestones alongside proactive liquidity management in a competitive immunotherapy landscape.